INOVIO's Breakthrough in DNA Medicine: Key Presentations at World Congress INOVIO will showcase its innovative DNA medicine technology at the upcoming World Federation of Hemophilia Congress in Kuala Lumpur, emphasizing breakthroughs in treating hemophilia.

INOVIO's Breakthrough in DNA Medicine: Key Presentations at World Congress #United_States #Kuala_Lumpur #INOVIO #DNA_medicines #Hemophilia

INOVIO Pharmaceuticals Reports Strong Financial Position and Advances in DNA Medicine Development INOVIO Pharmaceuticals announces significant developments, including FDA acceptance of its BLA for INO-3107 and updates on financial performance for 2025.

INOVIO Pharmaceuticals Reports Strong Financial Position and Advances in DNA Medicine Development #USA #INOVIO #DNA_medicines #Plymouth_Meeting #INO-3107

INOVIO to Showcase Groundbreaking DNA Medicine Innovations at Major Scientific Conferences INOVIO is set to participate in key scientific conferences, presenting advances in DNA medicine aimed at treating HPV-related diseases and COVID-19.

INOVIO to Showcase Groundbreaking DNA Medicine Innovations at Major Scientific Conferences #United_States #INOVIO #DNA_medicines #Plymouth_Meeting #HPV

Advancing glioblastoma treatment: Akeso and INOVIO's collaboration on innovative therapies Akeso and INOVIO have teamed up to explore a novel combination therapy for glioblastoma, aiming to improve treatment options and patient outcomes in clinical settings.

Advancing glioblastoma treatment: Akeso and INOVIO's collaboration on innovative therapies #China #Hong_Kong #Glioblastoma #Akeso #INOVIO

Innovative Collaboration in Cancer Treatment: INOVIO and Akeso Join Forces for Glioblastoma Therapy INOVIO Pharmaceuticals and Akeso team up to explore a promising therapy for glioblastoma, combining cutting-edge immunotherapy with advanced treatments to tackle this aggressive brain cancer.

Innovative Collaboration in Cancer Treatment: INOVIO and Akeso Join Forces for Glioblastoma Therapy #United_States #Akeso #Cadonilimab #INOVIO #Plymouth_Meeting

INOVIO Announces Participation in Key Scientific and Investor Conferences for 2026 INOVIO will engage in crucial scientific and investor conferences in 2026, showcasing advancements in DNA medicines targeting HPV and cancer.

INOVIO Announces Participation in Key Scientific and Investor Conferences for 2026 #United_States #INOVIO #DNA_medicines #Plymouth_Meeting #HPV

Robbins LLP Alerts IINO Stockholders of the Class Action Against Inovio Pharmaceuticals Inc. This article discusses Robbins LLP's reminder for IINO stockholders regarding a class action lawsuit against Inovio Pharmaceuticals related to misleading investor information.

Robbins LLP Alerts IINO Stockholders of the Class Action Against Inovio Pharmaceuticals Inc. #United_States #San_Diego #Robbins_LLP #INOVIO #IINO

FDA Reviews INOVIO's Biologics License Application for INO-3107 in RRP Treatment INOVIO's INO-3107 is under review by the FDA for treating adults with recurrent respiratory papillomatosis, aiming to offer a non-surgical alternative.

FDA Reviews INOVIO's Biologics License Application for INO-3107 in RRP Treatment #United_States #INOVIO #Plymouth_Meeting #INO-3107 #HPV-related_diseases

INOVIO Pharmaceuticals Announces Employee Equity Grant Under Inducement Plan for New Talent Acquisition INOVIO Pharmaceuticals has granted an equity award to a new hire under its Inducement Plan, aimed at attracting talent for advancing DNA medicines.

INOVIO Pharmaceuticals Announces Employee Equity Grant Under Inducement Plan for New Talent Acquisition #USA #biotechnology #INOVIO #DNA_medicines #Plymouth_Meeting

INOVIO Pharmaceuticals Highlights Progress in Third Quarter 2025 Financial Results INOVIO Pharmaceuticals presents its financial results for Q3 2025, focusing on its advancements including the BLA for INO-3107 and new vaccine technologies.

INOVIO Pharmaceuticals Highlights Progress in Third Quarter 2025 Financial Results #USA #INOVIO #Plymouth_Meeting #INO-3107 #DNA_medicine

INOVIO Pharmaceuticals Announces Equity Grant Under Inducement Plan INOVIO Pharmaceuticals has reported an equity grant to a new employee under its Inducement Plan, designed to enhance DNA medicines development.

INOVIO Pharmaceuticals Announces Equity Grant Under Inducement Plan #United_States #biotechnology #INOVIO #DNA_medicines #Plymouth_Meeting

INOVIO Set to Participate in Upcoming Biotechnology Conference Focusing on DNA Medicines INOVIO, a leader in DNA medicine development, will join the Stephens Biotechnology Virtual Conference. Key management will discuss innovative healthcare solutions.

INOVIO Set to Participate in Upcoming Biotechnology Conference Focusing on DNA Medicines #United_States #biotechnology #INOVIO #Plymouth_Meeting #DNA_medicine

Recent Findings on DNA-Encoded Monoclonal Antibodies Represent a Major Breakthrough in Medicine A new study published in Nature Medicine shows promising results for DNA-Encoded Monoclonal Antibodies in combating diseases like COVID-19, revealing their effective and durable performance over 72 weeks.

Recent Findings on DNA-Encoded Monoclonal Antibodies Represent a Major Breakthrough in Medicine #USA #INOVIO #Plymouth_Meeting #COVID-19 #DMAbs

INOVIO's Upcoming Conference Presentations: Exploring Advances in DNA Medicines INOVIO announces its participation in significant scientific conferences, showcasing its innovative DNA medicines and promising treatments.

INOVIO's Upcoming Conference Presentations: Exploring Advances in DNA Medicines #USA #INOVIO #DNA_medicines #Plymouth_Meeting #HPV-related_diseases

INOVIO Advances BLA Submission for INO-3107 Targeting Recurrent Respiratory Papillomatosis in Adults INOVIO is set to submit a rolling Biologics License Application for INO-3107, targeted at treating adults with Recurrent Respiratory Papillomatosis (RRP).

INOVIO Advances BLA Submission for INO-3107 Targeting Recurrent Respiratory Papillomatosis in Adults #United_States #INOVIO #Plymouth_Meeting #INO-3107 #RRP

INO-3107 Shows Promise in Reducing Surgeries for Recurrent Respiratory Papillomatosis Patients Recent studies indicate that INO-3107 significantly lowers the need for surgeries in patients with Recurrent Respiratory Papillomatosis, highlighting its potential.

INO-3107 Shows Promise in Reducing Surgeries for Recurrent Respiratory Papillomatosis Patients #United_States #INOVIO #Plymouth_Meeting #INO-3107 #RRP

INOVIO's Revolutionary DNA Medicines to be Highlighted at Orphan Drug Summit INOVIO is set to showcase innovative DNA medicine technology at the upcoming Orphan Drug Summit in Boston, focusing on rare diseases and cancer treatments.

INOVIO's Revolutionary DNA Medicines to be Highlighted at Orphan Drug Summit #USA #Boston #INOVIO #DNA_medicines #Orphan_Drug_Summit

INOVIO Set to Showcase Innovations at Key Scientific and Investor Conferences INOVIO Pharmaceuticals will present critical data and insights on its innovative DNA medicines at several key conferences, including the groundbreaking ABEA at COSM.

INOVIO Set to Showcase Innovations at Key Scientific and Investor Conferences #USA #INOVIO #Plymouth_Meeting #HPV #ABEA

INOVIO Set to Showcase Innovations at Upcoming Scientific Conferences INOVIO will present its DNA medicine advancements, including its key candidate for HPV-related diseases, at notable upcoming conferences.

INOVIO Set to Showcase Innovations at Upcoming Scientific Conferences #United_States #INOVIO #Plymouth_Meeting #DNA_medicine #HPV

INOVIO Pharmaceuticals: Advancements in DNA Medicines and BLA Application Progress INOVIO Pharmaceuticals shares key achievements and financial updates, highlighting progress towards submitting a BLA for INO-3107 and clinical innovations.

INOVIO Pharmaceuticals: Advancements in DNA Medicines and BLA Application Progress #United_States #INOVIO #DNA_medicines #Plymouth_Meeting #BLA

INOVIO Unveils Striking Interim Results from Innovative COVID-19 DMAbs Trial INOVIO Pharmaceuticals has released hopeful interim results from its Phase 1 trial assessing DNA-encoded monoclonal antibodies for COVID-19, showcasing sustained antibody levels over 72 weeks.

INOVIO Unveils Striking Interim Results from Innovative COVID-19 DMAbs Trial #USA #INOVIO #Plymouth_Meeting #COVID-19 #DMAbs

Promising Clinical Insights of INO-3107 for Recurrent Respiratory Papillomatosis Treatment Recent clinical data published shows INO-3107's potential to significantly reduce surgeries for RRP patients while enhancing immune response.

Promising Clinical Insights of INO-3107 for Recurrent Respiratory Papillomatosis Treatment #USA #INOVIO #Plymouth_Meeting #INO-3107 #RRP

Presentation Planned for INO-3107's Immune Response Data at Upcoming AACR-IO Conference INOVIO will showcase groundbreaking research on INO-3107's immune response during the AACR-IO Conference, highlighting its efficacy in combating HPV-related diseases.

Presentation Planned for INO-3107's Immune Response Data at Upcoming AACR-IO Conference #United_States #INOVIO #Plymouth_Meeting #INO-3107 #HPV-6

INOVIO Announces New Equity Grant to Support Innovative DNA Medicine Development INOVIO Pharmaceuticals reveals an equity grant for a new employee under its Inducement Plan, focusing on DNA medicines for infection and cancer.

INOVIO Announces New Equity Grant to Support Innovative DNA Medicine Development #United_States #INOVIO #DNA_medicines #equity_grant #Plymouth_Meeting